Article thumbnail

Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy

By Valerie Beral, Gillian Reeves, Diana Bull and Jane Green
Topics: Articles
Publisher: Oxford University Press
OAI identifier: oai:pubmedcentral.nih.gov:3039726
Provided by: PubMed Central

Suggested articles

Citations

  1. Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses.
  2. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.
  3. Blood pressure, stroke, and coronary heart-disease. Part 1. Prolonged differences in blood-pressure: prospective observational studies corrected for the regression dilution bias.
  4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results.
  5. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer.
  6. Declining breast cancer incidence and decreased HT use.
  7. Endogenous Hormones and Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women.
  8. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.
  9. Estrogen-progestogen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?
  10. (2004). Etiology of hormone receptor–defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev.
  11. (1991). Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med.
  12. (2008). for Research on Cancer. Monograph on the Evaluation of Carcinogenic Risks to Humans.
  13. (1999). for Research on Cancer. Monograph on the Evaluation of Carcinogenic Risks to Humans. Hormonal Contraception and Post-Menopausal Hormonal Therapy. Vol 72.
  14. Healthcare products Regulatory Agency. UK Public Assessment Report. Hormone-Replacement Therapy: Safety Update.
  15. (2001). Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen.
  16. Incidence of breast-cancer risk and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci.
  17. (2006). Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection. Cancer Epidemiol Biomarkers Prev.
  18. (1991). Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates
  19. Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study.
  20. (2003). The decrease in breast-cancer incidence in
  21. The Women’s Health Initiative Randomized Controlled Trial. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy.
  22. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.